# Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.

> **NCT05295680** · PHASE2 · RECRUITING · sponsor: **Aparna Goel** · enrollment: 24 (estimated)

## Conditions studied

- Primary Sclerosing Cholangitis

## Interventions

- **DRUG:** Hymecromone

## Key facts

- **NCT ID:** NCT05295680
- **Lead sponsor:** Aparna Goel
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-10
- **Primary completion:** 2027-05
- **Final completion:** 2027-12
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05295680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05295680, "Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05295680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*